Literature DB >> 17038682

Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs.

Alyson Auliff1, Danny W Wilson, Bruce Russell, Qi Gao, Nanhua Chen, Le Ngoc Anh, Jason Maguire, David Bell, Michael T O'Neil, Qin Cheng.   

Abstract

The increasing use of sulfadoxine-pyrimethamine (SP) for the treatment of chloroquine-resistant Plasmodium falciparum has resulted in increased reports of SP resistance of P. falciparum worldwide. Selection of SP-resistant Plasmodium vivax in areas where P. falciparum and P. vivax co-exist is not entirely clear. We examined the prevalence and extent of point mutations in pvdhfr and pvdhps in 70 P. vivax isolates from China, East Timor, Papua New Guinea (PNG), Philippines, Vanuatu, and Vietnam. Mutations in seven codon positions were found in pvdhfr, with the majority of isolates having double mutations (S58R/S117N). The greatest range of mutations was observed in the PNG and Vanuatu isolates, ranging from single to quadruple mutations (F57L/S58R/T61M/S117T). Single mutations in pvdhps were observed only in parasites with mutations in corresponding pvdhfr. Parasites with the S58R/S117N dhfr allelic type showed an MIC level for pyrimethamine and cycloguanil comparable to that previously reported, but were susceptible to WR99210.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038682

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  48 in total

1.  The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R, and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates.

Authors:  Sébastien Briolant; Hervé Bogreau; Marine Gil; Housem Bouchiba; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum.

Authors:  S Kaewpongsri; K Sriprawat; R Suwanarusk; D E Kyle; U Lek-Uthai; M Leimanis; K M Lwin; A P Phyo; J Zwang; B Russell; F Nosten; L Renia
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

3.  Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.

Authors:  Patricia Mula; Amalia Fernández-Martínez; Aida de Lucio; Jose Manuel Ramos; Francisco Reyes; Vicenta González; Agustín Benito; Pedro Berzosa
Journal:  Malar J       Date:  2011-08-02       Impact factor: 2.979

4.  In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Authors:  Feng Lu; Qi Gao; Kesinee Chotivanich; Hui Xia; Jun Cao; Rachanee Udomsangpetch; Liwang Cui; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

5.  Role of Plasmodium vivax Dihydropteroate Synthase Polymorphisms in Sulfa Drug Resistance.

Authors:  Wichai Pornthanakasem; Pinpunya Riangrungroj; Penchit Chitnumsub; Wanwipa Ittarat; Darin Kongkasuriyachai; Chairat Uthaipibull; Yongyuth Yuthavong; Ubolsree Leartsakulpanich
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Assessing the genetic diversity of the aldolase genes of Plasmodium falciparum and Plasmodium vivax and its potential effect on performance of aldolase-detecting rapid diagnostic tests.

Authors:  Nelson Lee; Joanne Baker; David Bell; James McCarthy; Qin Cheng
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

7.  Genetic structure of Plasmodium vivax and Plasmodium falciparum in the Bannu district of Pakistan.

Authors:  Lubna Khatoon; Frederick N Baliraine; Mariangela Bonizzoni; Salman A Malik; Guiyun Yan
Journal:  Malar J       Date:  2010-04-23       Impact factor: 2.979

8.  Molecular surveillance of Plasmodium vivax dhfr and dhps mutations in isolates from Afghanistan.

Authors:  Sedigheh Zakeri; Mandana Afsharpad; Faezeh Ghasemi; Ahmad Raeisi; Najibullah Safi; Waqar Butt; Hoda Atta; Navid D Djadid
Journal:  Malar J       Date:  2010-03-14       Impact factor: 2.979

9.  Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.

Authors:  Michael H Kinzer; Krisin Chand; Hasan Basri; Edith R Lederman; Augustina I Susanti; Iqbal Elyazar; George Taleo; William O Rogers; Michael J Bangs; Jason D Maguire
Journal:  Malar J       Date:  2010-04-06       Impact factor: 2.979

Review 10.  Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.

Authors:  Ric N Price; Sarah Auburn; Jutta Marfurt; Qin Cheng
Journal:  Trends Parasitol       Date:  2012-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.